NCT05118958View on ClinicalTrials.gov

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Hereditary Angioedema
Interventions
DRUG

KVD824 Prototype 1 modified-release tablet

300 mg modified-release tablet

DRUG

KVD824 Prototype 2 modified-release tablet

300 mg modified-release tablet

DRUG

KVD824 Immediate-Release Capsule

300 mg immediate-release capsule

DRUG

Placebo to KVD824 Prototype 1

Placebo to 300 mg KVD824 Prototype 1 modified-release tablet

DRUG

KVD824 Prototype 3 modified-release tablet

300 mg modified-release tablet

Trial Locations (1)

Unknown

KalVista Investigative Site, Nottingham

Sponsors
All Listed Sponsors
lead

KalVista Pharmaceuticals, Ltd.

INDUSTRY

NCT05118958 - Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations | Biotech Hunter | Biotech Hunter